文献速递中医内科中药与中成药合理使用

尿毒清颗粒对非透析CKD 3-5期患者的长期疗效:回顾性队列研究

A Chinese patent medicine's long-term efficacy on non-dialysis patients with CKD stages 3-5: a retrospective cohort study.
PubMed 文献 · Front Pharmacol · 2024-04-26

该回顾性队列纳入1271例CKD 3-5期非透析患者,按是否服用尿毒清颗粒分组,中位随访29.71个月。尿毒清组SCr变化优于对照组,复合终点风险显著降低(模型3 HR 0.602,95%CI 0.442-0.820,p=0.001),长期用药使CKD进展风险降低39.8%。

要点

  • 尿毒清颗粒长期服用与SCr变化改善相关
  • 复合终点(RRT、eGFR<5、eGFR下降≥50%或SCr翻倍)风险降低
  • 用药组生存概率显著高于非用药组(p=0.0039)

核心结论

  • 长期使用尿毒清颗粒改善SCr变化并降低CKD进展风险39.8%。

研究设计与样本

  • 回顾性队列研究,纳入1271例CKD 3-5期非透析患者,按是否服用尿毒清颗粒分组。
  • 中位随访29.71(12.10,56.07)个月,采用广义线性混合模型比较SCr变化,多因素Cox回归分析复合终点。

主要发现

  • 基线SCr Z评分均值非尿毒清组为-0.175,尿毒清组为0.153(p=0.015)。
  • 尿毒清组第1至第4次访视GLMM系数分别为-0.207(95%CI -0.346,-0.068,p=0.004)、-0.214(95%CI 0.389,-0.039,p=0.017)、-0.324(95%CI 0.538,-0.109,p=0.003)、-0.502(95%CI 0.761,-0.243,p=0.000)。
  • 第5次访视系数为-0.252(95%CI 0.569,0.065,p=0.119)。
  • 尿毒清组生存概率显著更高(p=0.0039)。
  • 复合终点风险:模型1 HR 0.654(95%CI 0.489-0.875,p=0.004),模型2 HR 0.646(95%CI 0.476,0.877,p=0.005),模型3 HR 0.602(95%CI 0.442,0.820,p=0.001)。

关键数值与推荐

  • 复合终点定义为接受肾脏替代治疗(RRT)、eGFR<5 mL/min/1.73 m2、eGFR较基线下降≥50%或SCr翻倍。

临床怎么用

  • 对CKD 3-5期非透析患者,可考虑长期使用尿毒清颗粒以延缓肾功能进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chinese patent medicine is commonly used in China as an important treatment mechanism to thwart the progression of chronic kidney disease (CKD) stages 3-5, among which Niaoduqing granules are a representative Chinese patent medicine; however, its long-term efficacy on CKD prognosis remains unclear. METHODS: Patients were grouped according to Niaoduqing granule prescription duration (non-Niaoduqing granule (non-NDQ) group vs Niaoduqing granule (NDQ) group). Serum creatinine (SCr) variation was compared using a generalized linear mixed model (GLMM). Multivariate Cox regression models were constructed, adjusting for confounding factors, to explore the risk of composite outcomes (receiving renal replacement therapy (RRT) or having an estimated glomerular filtration rate (eGFR)<5 mL/min/1.73 m2, ≥50% decline in the eGFR from the baseline, and doubling of SCr) in individuals consuming Niaoduqing granules. RESULTS: A total of 1,271 patients were included, with a median follow-up duration of 29.71 (12.10, 56.07) months. The mean SCr Z-scores for the non-NDQ group and NDQ group were -0.175 and 0.153, respectively, at baseline (p = 0.015). The coefficients of the NDQ group from visit 1 to visit 5 were -0.207 (95% CI: -0.346, -0.068, p = 0.004), -0.214 (95% CI: 0.389, -0.039, p = 0.017), -0.324 (95% CI: 0.538, -0.109, p = 0.003), -0.502 (95% CI: 0.761, -0.243, p = 0.000), and -0.252 (95% CI: 0.569, 0.065, p = 0.119), respectively. The survival probability was significantly higher in the NDQ group (p = 0.0039). Taking Niaoduqing granules was a significant protective factor for thwarting disease progression (model 1: HR 0.654 (95% CI 0.489-0.875, p = 0.004); model 2: HR 0.646 (95% CI 0.476, 0.877, p = 0.005); and model 3: HR 0.602 (95% CI 0.442, 0.820, p = 0.001)). CONCLUSION: The long-term use of Niaoduqing granules improved SCr variation and lowered the risk of CKD progression by 39.8%.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Chen HF, Lin YJ, Han Y, et al. A Chinese patent medicine's long-term efficacy on non-dialysis patients with CKD stages 3-5: a retrospective cohort study. Front Pharmacol. 2024. PMID: 38738180. doi:10.3389/fphar.2024.1379338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。